Advanced Solutions
for Advanced Pathology
BCA-225 (Cu-18)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45293 IMPATH BCA-225 RTU M (Cu-18)
50 Tests
44204 BCA-225 RTU M (CU-18)
7 ml Ready To Use
44433 BCA-225 0,1 M (CU-18)
100 µl liquid Concentrated
44434 BCA-225 1 M (CU-18)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Breast carcinoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
BCA-225 is a glycoprotein identified in human breast carcinoma cells that has been reported to show a restricted distribution in other human
tissues. However, one study showed that BCA-225 expression was found to be common in adenocarcinomas of the breast (98%), kidney (94%),
ovary (80%), and lung (74%) but was infrequent in adenocarcinomas of gastrointestinal tract (10%-16%). Adenocarcinomas of the prostate, bile
ducts, thyroid, endometrium, endocervix, and pancreas showed an intermediate frequency of BCA-225 expression (36%-68%). Hepatocellular
carcinomas showed no reactivity for BCA-225. Anti-BCA-225, used in conjunction with antibodies against CEA, CA19-9, and CA125, is a useful
marker for detecting the origin of common metastatic adenocarcinomas (BCA225-, CEA+, and CA125- for colon tumors; BCA225+, CEA+ and
CA19-9- for lung tumors; BCA225+, CEA- and CA125- for breast tumors). Anti-BCA-225 is also useful in discriminating adenocarcinoma from
reactive mesothelium in cell block preparations.
Carcinoma: Differential Diagnosis
BCA-225
Androgen
Receptor
GCDFP-15
ER/PR
Mammaglobin
PSA/PSAP
Salivary Duct Carcinoma
+
+
+
-
-
-
Breast Carcinoma
+
+(apocrine)
+
+
+
-
Prostate Carcinoma
-
+
-
-
-
+
Reference
1. Ceriani RL. Monoclonal Ab’s and breast cancer. Boston, Martinus, Nijhoff, 1985.
2. Mesa-Tejada R, et al. Am J Pathol. 1988; 130:305-314.
3. Loy TS, et al. Am J Clin Pathol. 1991 Sep; 96(3):326-9.
4. Ma CK, et al. Am J Clin Pathol. 1993 May; 99(5):551-7.
29
